Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease

Lin-Pierre Zhao^#^{1

2}, Berenice Schell^#^{2

3}, Marie Sébert^{1

4}, Rathana Kim³, Pierre Lemaire³, Maxime Boy², Stephanie Mathis³, Lise Larcher^{3

4}, Clémentine Chauvel³, Mohamed Bedis Dhouaieb³, Valéria Bisio², Claude Preudhomme^{5

6}, Alice Marceau-Renaut^{5

6}, Raphaël Itzykson^{1

4}, Arsène Mekinian⁷, Olivier Fain⁷, Antoine Toubert^{2

8}, Pierre Fenaux¹, Nicolas Dulphy^{2

8}, Emmanuelle Clappier^{3

4}, Lionel Adès⁹

Affiliations

¹ Université de Paris, Department of Hematology, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
² Université de Paris, Institut de Recherche Saint-Louis, EMiLy, INSERM U1160, Paris, France.
³ Université de Paris, Laboratory of Hematology, AP-HP, Hôpital Saint-Louis, Paris, France.
⁴ Université de Paris, Institut de Recherche Saint-Louis, INSERM U944, Paris, France.
⁵ Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France.
⁶ INSERM Lille, University of Lille, Lille, France.
⁷ Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Hôpital Saint-Antoine, AP-HP, Paris, France.
⁸ Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France.
⁹ Université de Paris, Department of Hematology, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France. lionel.ades@aphp.fr.

^# Contributed equally.

Lin-Pierre Zhao et al. Leukemia. 2021 Sep.

. 2021 Sep;35(9):2731-2733.

doi: 10.1038/s41375-021-01353-8. Epub 2021 Aug 3.

¹ Université de Paris, Department of Hematology, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
² Université de Paris, Institut de Recherche Saint-Louis, EMiLy, INSERM U1160, Paris, France.
³ Université de Paris, Laboratory of Hematology, AP-HP, Hôpital Saint-Louis, Paris, France.
⁴ Université de Paris, Institut de Recherche Saint-Louis, INSERM U944, Paris, France.
⁵ Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France.
⁶ INSERM Lille, University of Lille, Lille, France.
⁷ Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Hôpital Saint-Antoine, AP-HP, Paris, France.
⁸ Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France.
⁹ Université de Paris, Department of Hematology, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France. lionel.ades@aphp.fr.

^# Contributed equally.

No abstract available

References

1. Winter S, Shoaie S, Kordasti S, Platzbecker U. Integrating the « Immunome » in the stratification of myelodysplastic syndromes and future clinical trial design. J Clin Oncol. 2020;38:1723–35. - DOI
1. Zhao L-P, Boy M, Azoulay C, Clappier E, Sébert M, Amable L, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021. https://doi.org/10.1038/s41375-021-01152-1 .
1. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. NEJM. 2020;383:2628–38. - DOI
1. Bourbon E, Heiblig M, Gerfaud-Valentin M, Barba T, Durel CA, Lega J-C, et al. Therapeutic options in Vexas syndrome: insights from a retrospective series. Blood. 2021;137:3682–4. - DOI
1. Gurnari C, Pagliuca S, Durkin L, Terkawi L, Awada H, Kongkiatkamon S, et al. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood. 2021;137:3685–9. - DOI